In June 2019, an online pharmacy in New Haven called Valisure ran a routine batch of ranitidine — better known as Zantac — through a mass spectrometer. CEO David Light's lab found NDMA, a probable human carcinogen, at over 3 million nanograms per tablet. The FDA's daily intake limit is 96.
Light filed a citizen petition that September. Six and a half months later, the FDA pulled every ranitidine product in America and a multibillion-dollar shelf went dark overnight. Famotidine factories ran around the clock, Pepcid demand surged so hard that the U.S. and Canada were stuck with shortages well into late 2021, and the entire migration got captured by whoever happened to have inventory and a story when the dust settled.
One online pharmacy with a mass spec ate a category that had been sitting on the shelf since 1981.
Multiply that shelf by twelve and you have today's idea: a reformulation arbitrage intelligence subscription that watches FDA monographs, USPTO filings, PubMed, and Amazon retail data, then tells indie founders, supplement operators, CPG investors, and brand studios which OTC categories are about to crack.
Sleep is the obvious wedge. Diphenhydramine has been the default sleep aid for decades, and a 2015 JAMA study tied heavy users to a 54% jump in dementia risk (imagine that landing on the FDA's desk the wrong Tuesday). The product is a weekly opportunity dossier with a three-tier pricing ladder running $499 to $7,500, and the synthesis across data sources is the moat. Forty paid seats across the lower two tiers gets you to roughly $35K MRR before any studio-tier deals close.
Read the full playbook here:
A small biotech just filed a patent on a caffeine-free Excedrin alternative — pointing at a broader gap: OTC categories worth billions, built on decades-old formulations.
From the Vault:
QVC filed for bankruptcy. Its core skill — live product selling — didn't. Here's how to build the outsourced live-commerce operating layer brands on TikTok Shop can't find.
U.S. retail vacancy sits at 4.8% while 7,900 stores are closing in 2026. The best boxes are gone before they're listed. Here's the gap no one has filled.
